Illumina Tells 5th Circ. Grail Case 'Flagrant' Overreach

By Matthew Perlman · June 6, 2023, 6:53 PM EDT

Illumina told the Fifth Circuit that the Federal Trade Commission's case challenging its $8 billion repurchase of cancer testing company Grail is "flagrant" overreach that is costing lives and highlights constitutional...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

Illumina v. FTC

Case Number

Court

Appellate - 5th Circuit

Nature of Suit

Agency

Date Filed

April 05, 2023

Recent Articles By Matthew

July 19, 2024
Boehringer Looks To Toss Inhaler Antitrust Case
July 17, 2024
Boehringer Wants Inhaler Antitrust Case Moved To Mass.
July 10, 2024
Buyers Say Teva Had Multipart Scheme To Delay Inhaler Rivals
July 09, 2024
FTC Says Drug Middlemen Inflate Costs, Squeeze Pharmacies
June 24, 2024
Justices Won't Hear Objections To $2.67B BCBS Deal
June 10, 2024
Health Data Co. Says Rival's Request Risks Patient Security
June 04, 2024
Nurse Staffing Exec Wants Antitrust, Fraud Charges Separated
May 28, 2024
HIV Drug Buyers Fight Bid To Combine 9th Circ. Appeal Briefs
May 24, 2024
Software-Aided Price Fixing Under Antitrust Assault
May 16, 2024
Gilead, Teva Want 17 HIV Drug Antitrust Appeals Consolidated